We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Translating an Efficacious Illness Management Intervention for Youth With Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03317977
Recruitment Status : Active, not recruiting
First Posted : October 23, 2017
Last Update Posted : May 3, 2022
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Deborah Ellis, Ph.D., Wayne State University

Brief Summary:
The propose of the study is to test the effectiveness of Reach for Control (RFC) as compared to Michigan MATCH to improve asthma symptoms, asthma management and lung functioning and to decrease ED visits and admissions for youth with poorly controlled asthma when integrated into hospital emergency departments and delivered by community health workers. The study is a hybrid implementation-effectiveness design and will test RFC for use in real world, public healthcare settings.

Condition or disease Intervention/treatment Phase
Asthma in Children Behavioral: Reach for Control Behavioral: MATCH Not Applicable

Detailed Description:
The study will be conducted in the emergency department at Children's Hospital of Michigan; CHM). 170 adolescents with poorly controlled asthma and their primary caregivers will be enrolled. Families will be randomly assigned to six months of home-based family treatment consisting of either RFC or Michigan MATCH , a model program endorsed by the State of Michigan for treatment of poorly controlled asthma. Treatment content of RFC consists of weekly sessions focusing on asthma education, asthma management skills, improving home-school community for asthma, access to care and case management. MATCH includes asthma education but is less intensive and does not focus on family management skills. Treatment will be provided by community health workers (CHWs) employed by a community agency providing MATCH as their standard of care. Consent and data collection will be completed in the home at baseline with additional data collection visits at 6, 12 and 18 months after baseline. Data collection is completed by project research assistants and consists of questionnaires and interviews with the adolescent and parent to assess asthma management, asthma symptoms and hospital utilization. The adolescent also completes a pulmonary function test on a portable spirometer and is observed using medication devices to assess asthma care skills objectively.The data analyses will be intent-to-treat, meaning that all randomized participants are included regardless of the intervention dose received. Trial data will analyzed using the linear mixed effect models.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 170 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Translating an Efficacious Illness Management Intervention for Youth With Poorly Controlled Asthma to Real World Settings
Actual Study Start Date : February 1, 2018
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : December 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: Reach for Control
Reach For Control is a multi-component, home-based family therapy that targets the multiple causes of poor adolescent asthma management across individual, family and community systems.
Behavioral: Reach for Control
In Phase 1 (weeks 1-4), the CHW conducts an initial intake and then completes a comprehensive functional analysis (FA) of behavior to determine the causes of poor asthma management for each youth regarding asthma management. In Phase 2 (weeks 5-20) is a treatment phase and consists of a combination of mandatory cognitive-behavioral skills training (CBST) modules (received by all families) and flexible CBST modules chosen and individualized based on the results of the Phase 1 FA. This includes but not limited to In-vivo Asthma Skills Training, Improving Family Communication and Behavioral Contracting. Phase 3 (weeks 21-24) involves termination planning and relapse prevention
Other Name: RFC

Active Comparator: Michigan MATCH
Program endorsed by the State of Michigan for treatment of poorly controlled asthma.
Behavioral: MATCH
Managing Asthma Through Case Management in Home (MATCH) is the current intervention provided by WCHAP to youth with poorly controlled asthma and their families.

Primary Outcome Measures :
  1. Pulmonary Functioning (FEV1) [ Time Frame: Change from Baseline at 6 months, change from Baseline at 12 months and change from Baseline at 18 months ]
    Spirometry will be obtained using a portable calibrated recording spirometer.

Secondary Outcome Measures :
  1. Family Asthma Management System Scale [ Time Frame: Change from Baseline at 6 months, change from Baseline at 12 months and change from Baseline at 18 months ]
    Identifies family strengths and weaknesses in the management of pediatric asthma across a variety of domains. This is a semi-structured interview that is rated on seven to nine 9-point subscales with higher scores indicating better management. The rating manual provides elaboration and brief examples at key anchor points for each rating scale. A FAMSS summary score is computed for each family by taking a mean across all subscales.

  2. Asthma Device Use Skills [ Time Frame: Change from Baseline at 6 months, change from Baseline at 12 months and change from Baseline at 18 months ]
    Observational measure where device use competency is rated during adolescent demonstration of use of their own quick relief and controller medication devices.

  3. Asthma Symptom Frequency [ Time Frame: Change from Baseline at 6 months, change from Baseline at 12 months and change from Baseline at 18 months ]
    Self report assessing wheezing, nighttime symptoms, speech limitations and activity limitations.

  4. Number of emergency department visits, hospitalizations, and total hospital days [ Time Frame: Change from Baseline at 3 months, Change from Baseline at 6 months, change from Baseline at 9 months, change from Baseline at 12 months, change from Baseline at 15 months and change from Baseline at 18 months ]
    Hospitalizations will be obtained from electronic medical records and service utilization forms

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:


  1. Child aged 12 years, 0 months to 16 years, 11 months
  2. Moderate to severe persistent asthma
  3. Child seen in the CHM emergency department for treatment of asthma exacerbation
  4. Child has experienced 2 or more ED visits and/ or inpatient admissions in prior 12 months (i.e. poorly controlled asthma)
  5. Parent/ legal guardian willing to participate in home-based family treatment
  6. Child and family resides within 20 miles of CHM (allows for home-based data collection and intervention)

Exclusion Criteria:


  1. Child is currently in an out-of-home placement
  2. Schizophrenia or other psychosis on the part of the youth or parent
  3. Current suicidality or homicidality on the part of the youth or parent
  4. Cognitive impairment or learning disability that prevents comprehension of research measures on the part of parent or youth

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03317977

Layout table for location information
United States, Michigan
Children's Hospital of Michigan
Detroit, Michigan, United States, 48201
Sponsors and Collaborators
Wayne State University
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
Principal Investigator: Deborah A Ellis, Ph.D Wayne State University
Layout table for additonal information
Responsible Party: Deborah Ellis, Ph.D., Professor of Family Medicine and Public Health Sciences, Wayne State University
ClinicalTrials.gov Identifier: NCT03317977    
Other Study ID Numbers: 071217MP4E
R01HL138633-01A1 ( U.S. NIH Grant/Contract )
First Posted: October 23, 2017    Key Record Dates
Last Update Posted: May 3, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data will be made available at the end of the study through presentations at scientific conferences and publications in peer-reviewed scientific journals. All final peer-reviewed manuscripts that result from the study will be submitted to PubMed Central. In addition, final dataset from the trial will be shared. Identifiers will be removed from the data prior to any release of the dataset.
Time Frame: Indefinitely
Access Criteria: In light of this and the sensitive nature of the treatment data contained in the data set, as well as the participation of children, data and associated documentation will be made available to users only under a specific data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying the data after analyses are completed. Furthermore, audiotaped session recordings will not be shared, as these include voice identifiers and it is not possible to de-identify the recordings; costs of transcription of sessions given their length and number are beyond the scope of the study.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Deborah Ellis, Ph.D., Wayne State University:
Asthma management, adolescents
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases